Marksans USFDA Approval Boost; Shares Rise 6.01%
By HDFC SKY | Published at: Apr 1, 2026 05:33 PM IST
Marksans Pharma secured USFDA approval for Benzonatate capsules, with shares rising over 6% on April 1, 2026.
Mumbai, April 1: Marksans Pharma Limited has received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Benzonatate Capsules USP in 100 mg and 200 mg strengths.
On paper, it is a standard generic approval. In practice, it adds another layer to the company’s presence in the US market.
Benzonatate is widely prescribed for cough and respiratory conditions. The company said in exchange disclosure that its product is bioequivalent to the reference listed drug, Tessalon capsules of Pfizer Inc.It allows Marksans to step into an existing prescription base rather than build demand from scratch.
Stock Market Snapshot
Marksans Pharma share price reacted positively to the development, with the stock gaining through the session.
As of 3:30 pm IST on April 1, 2026, the stock was trading at ₹166.32, up ₹9.43 or 6.01%, as per exchange data. The move was relatively firm, with the stock holding near its upper range.
The Marksans Pharma share price trend suggests that regulatory approvals in the US continue to act as clear triggers. Investors tend to assign value not just to the product itself, but to what it signals about the company’s pipeline and compliance track record.
Building The US Business, Step By Step
Marksans Pharma operates in regulated markets where approvals are both a barrier and a gateway.
The company’s approach has been incremental. Instead of relying on a few large launches, it continues to add products across therapeutic areas such as respiratory, pain management and cardiovascular.
Its manufacturing facilities, approved by regulators including the USFDA, support this model.
Conclusion
The Benzonatate approval does not transform the business overnight. That distinction is often how the generics space works. Progress is measured in accumulation, not sudden shifts. The market reaction on April 1, 2026 reflects that understanding.
Source:
- https://www.nseindia.com/get-quote/equity/MARKSANS/Marksans-Pharma-Limited
- https://nsearchives.nseindia.com/corporate/MARKSANS_01042026121732_SEIntimation.pdf
Disclaimer
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations
